Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Nov;23(11):2525-35.
doi: 10.1007/s11095-006-9137-8. Epub 2006 Oct 20.

PAMPA - excipient classification gradient map

Affiliations

PAMPA - excipient classification gradient map

Stefanie Bendels et al. Pharm Res. 2006 Nov.

Abstract

The effect of excipients on the artificial membrane permeability (Double-Sink PAMPA) properties of eight sparingly soluble drugs was studied. Quantities of excipient were selected to match the concentrations expected in the gastrointestinal fluid under clinically relevant conditions. Over 1,200 measurements were performed. To correct for the effects of the aqueous boundary layer and determine the intrinsic permeability, precisely measured ionization constants were used. The intrinsic permeability of weak acids was enhanced (up to 100 fold) but that of weak bases depressed (up to 270 fold) by the excipients: mefenamic acid > glybenclamide > progesterone > griseofulvin > clotrimazole > astemizole > dipyridamole > butacaine. Excipient enhancement ranked: 3 mM NaTC > 0.24% PEG400 > 0.2 M KCl > 0.24% NMP > 5% PEG400 > 0.24% PG > 1% PEG400 > 0.1M KCl > 1% PG > 1% NMP > 5% PG > 0.24% HP-beta-CD > 1% HP-beta-CD > 15 mM NaTC. The study clearly indicates that the method is suitable for use in preclinical development to assess the effect of excipients on the permeability of sparingly soluble drug candidates. The method is quick, cost-effective, and reasonably accurate. The self-rank-ordered PAMPA-Mapping may be a helpful visualization tool for delivery screening.

PubMed Disclaimer

References

    1. Eur J Pharm Sci. 2004 Aug;22(5):365-74 - PubMed
    1. Eur J Pharm Sci. 2005 Mar;24(4):333-49 - PubMed
    1. Eur J Pharm Sci. 2004 May;22(1):33-41 - PubMed
    1. Pharm Res. 2000 Jan;17(1):85-9 - PubMed
    1. Eur J Pharm Sci. 2003 Dec;20(4-5):393-402 - PubMed

LinkOut - more resources